Bold Science. Better Outcomes.
At EvolveImmune, we harness our “Immunology First” approach to create first-in-category cancer medicines to transform the lives of patients by delivering superior, long-term outcomes compared to current anti-cancer therapies.
We are pioneers who rapidly translate discoveries into innovations and innovations into differentiated therapeutic solutions, to address the most significant unmet medical needs in oncology.
We leverage exceptional experience in immunology to swiftly advance our modular, precision biotherapeutics platform to exploit the full potential of the array of unprecedented and validated immuno-oncology targets which comprise our pipeline.
We embrace collaborative team science to drive our success. We are scientifically curious and are highly agile problem-solvers. Our ambitions demand that we always remain both resilient and relentless.
EvolveImmune (EV) was founded to advance groundbreaking immune cell target discovery, originating from the Sidi Chen Laboratory at Yale University. Since our launch in 2020, we have built a fully integrated, world-class immunobiology and biotherapeutics team which is actively confronting the biggest challenges in cancer.
Our Science
Our approach to changing the course of cancer is simple: durable immune activation, where it matters.
Bold Science
EvolveImmune’s proprietary immunobiologics platform delivers both sustained immune activation and tumor cell targeting in a single agent. Through integrated signaling, EV’s first in category biologics directly target tumor cells and provide potent, tissue-localized amplification of cytokine secretion at the tumor site to maximize tumor killing.
Better Outcomes
Our biotherapeutics are engineered to overcome limitations of conventional CD3 bispecifics and other immune therapies to offer a better future for our patients in need, by maximizing therapeutic benefit and minimizing toxicity.
EVOLVE Platform: a first in-concept, multi-functional antibody
Our Pipeline
Our lead program, EVOLVE-104, is a first-in-category therapeutic with potential to address a wide range of solid tumors with high selectivity. EVOLVE-101 is a first-in-category therapeutic for B cell malignancies and AML. EvolveImmune will move both programs rapidly to clinical trials.
First-in-category
First-in-category
Best-in-class
First-in-class
Highly differentiated
Collaborations:
We have ongoing and emerging partnerships with leading academic and oncology centers to advance our pioneering science. Yale University, the Technology Incubation Program (TIP) at the University of Connecticut are among our key collaborators. We utilize the services of a number of premium contract organizations, so that our scientific team can continue to focus on discovering and delivering EvolveImmune’s breakthrough innovations.
Our Team
Leadership
Stephen Bloch, MD
Co-founder and CEO
As an entrepreneur, venture capitalist and former practicing physician, Steve knows firsthand the challenges of building successful healthcare companies. Unfazed by complexity in healthcare, whether scientific, regulatory, or market driven, Steve’s mission has been to make healthcare delivery more effective and affordable.
Before co-founding EvolveImmune, Steve helped start and finance leading healthcare companies as a general partner at Canaan Partners. Steve has served on the boards of companies in biopharma, digital health, medical devices and diagnostics, often as board chairman. Steve is currently chairman of the board at Liquidia (LQDA-NASDAQ), executive chairman of Allyx Therapeutics and is a member of Dartmouth Medical School’s Board of Advisors.
Before joining Canaan in 2002, Steve helped found and manage multiple start-ups, including RMS, one of the first radiology benefits companies where he was CEO for 6 years. Previously, Steve was a strategic pharmaceutical consultant for Arthur D. Little and a Ewing Marion Kauffman Fellow.
Steve obtained his AB from Dartmouth College, a MA in the history of science from Harvard, and his medical degree from the University of Rochester. Steve completed his residency at Massachusetts General Hospital/Harvard Medical School (radiology) and Lenox Hill Hospital/Cornell Medical School (internal medicine).
Jay Fine, PhD
President, Research and Development
Jay brings over 30 years of drug discovery and development experience, including strong strategic leadership in discovery research, translational sciences and biomarker research covering immunology, inflammatory diseases and tissue fibrosis.
Prior to joining EvolveImmune, Jay was the Senior Vice President and Global Therapeutic Area Head for Immunology & Respiratory Diseases Research at Boehringer Ingelheim, as well as the US Discovery Research Site Head at their Ridgefield, CT headquarters. Jay’s teams played seminal roles in the advancement of Skyrizi™ and in the discovery and development of spesolimab, and delivered over 25 molecules into clinical development.
Previously, Jay held positions of increasing responsibility at Roche, Schering-Plough and the National Cancer Institute. He received his BS degree from Cornell University and his Ph.D. degree from the University of Rochester Medical Center. He is the author of over 75 scientific publications and patents, and has received numerous honors and awards throughout his career.
Jeremy Myers, PhD
Senior Vice President, Research and Development
Jeremy Myers leads EvolveImmune’s biology and biotherapeutic research teams.
Before joining EV Jeremy helped lead Pfizer oncology research and development in Pearl River, NY as senior director, head of the Integrative Biotechnology Group. He was a member of Pfizer Oncology Research and Development Leadership Team. During his tenure, Jeremy led development of tumor targeted immunotherapies leveraging antibody discovery and rational protein design, cell surface antigen discovery efforts and interrogation of biotherapeutic targets for antibody drug conjugates and T-cell retargeting bispecific antibody therapeutics.
Before Pfizer, Jeremy was a research faculty member and AstraZeneca Research Fellow in the Department of Biochemistry at Vanderbilt University Medical School. Jeremy received his BSc in biology from Bucknell University. He completed his Ph.D. studies in biochemistry and molecular biology at the LSU Health Sciences Center and Louisiana State University. He completed a postdoctoral fellowship at Vanderbilt University.
Louis Matis, MD
Senior Advisor to CEO and Chairman of Scientific Advisory Board
Louis A. Matis, M.D. is the senior advisor to CEO and chairman of the EvolveImmune Scientific Advisory Board
Louis has more than 30 years of broad-based experience and expertise encompassing clinical medicine, drug development, regulatory affairs, basic and clinical biomedical research, and executive leadership in biotechnology. Prior to EvolveImmune, Louis was the senior vice president and chief development officer at Pieris Pharmaceuticals from 2015-2020. He has also served as an executive director at Alexion Pharmaceuticals (2011-2015), as president and CEO of the Immune Tolerance Institute (2006-2011) and as president and CEO of CGI Pharmaceuticals (2000-2006). Louis began his career in biotechnology at Alexion Pharmaceuticals in 1993, where he was the company’s first chief scientific officer. Louis has held senior research and clinical positions at the National Cancer Institute, National Institutes of Health, and the FDA Center for Biologics Evaluation and Research.
Louis completed his clinical training in internal medicine at the University of Chicago and in medical oncology at the National Cancer Institute. He received his M.D. degree from the University of Pennsylvania, where he currently serves on the Board of Trustees, and his BA degree, summa cum laude, from Amherst College. Louis has received the NIH Award of Merit, FDA’s Commendable Service Award, and was elected to membership in the American Society for Clinical Investigation. Louis is the author of over 120 publications in the fields of immunology, cell and molecular biology, and clinical medicine, published in journals including Nature, Science, Cell, and the Proceedings of the National Academy of Sciences.
Jennifer Gabler
Chief Financial Officer
Jen has over twenty five years of experience as a CFO for venture backed and startup companies.
As the CFO for Extraprise (now Vericast), a marketing services company, Jen built finance, HR, IT and back office operations plus helped lead global M&A efforts. She has also been the CFO for Aldea Pharmaceuticals and Butterfly Health, and provided financial project support for Marinus Pharmaceuticals (MRNS-NASDAQ) and Allyx Therapeutics. Jen began her career as an investment banking analyst at Merrill Lynch, and was the Northeast controller and a senior manager in entrepreneurial services at Coopers & Lybrand.
Jen co-founded The Refinery (www.refineryct.com), an accelerator for early stage companies with diverse management teams. She is also a founding partner of Marlborough Street Partners (www.marlboroughst.com) which provides strategic and operational services for investors and venture-funded companies.
Jen has an AB from Dartmouth College, an MBA from Columbia Business School and is a licensed CPA. She has been a lecturer and researcher at both Tuck and Harvard Business Schools.
Board of Directors
Board Observer
Scientific Advisory Board
SVP, Global Head Oncology and Hematology Drug Development - Genentech Roche
Former Physician-in-Chief Yale-Smilow Cancer Center
Former SVP Biologics Discovery, Oncology Discovery - Bristol-Myers Squibb
Partnered w/ Jim Allison on CTLA-4 drug development
Leader of the Melanoma/Renal Cancer Translational Team, Former president Society of Immunotherapy in Cancer (SITC)
Founders
Working with the best
Investors
News
EvolveImmune Therapeutics Reports Preclinical Data Highlighting Deep and Durable Anti-Tumor Efficacy with EV-104 in Presentation at 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Read More
EvolveImmune Therapeutics Presents Promising Preclinical Data from Novel Costimulatory T Cell Engager Platform at American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy
Read More
EvolveImmune Therapeutics to Present New Preclinical Data from Novel Costimulatory T Cell Engager Platform at Upcoming Scientific Conferences
Read More
EvolveImmune Therapeutics Appoints Jay Fine, Ph.D., as President of Research and Development
Read More
EvolveImmune celebrates opening of state-of-the-art lab and office complex in Branford, Connecticut
Read MoreCareers
Bold scientists seeking better outcomes for patients.
At EvolveImmune, we are building an exceptional team to bring our ambitions to life. If you are looking for a home for your talents, and you enjoy the camaraderie and hands-on environment of a startup biotechnology company, we invite you to apply.
EvolveImmune offers attractive compensation and benefits including a 401K plan with a generous company match as well as health & wellness benefits.
Job Openings
Who We Are:
EvolveImmune Therapeutics is a next-generation immunotherapy platform company based in the Yale/New Haven biotechnology ecosystem with laboratories in Branford and Farmington, CT. EvolveImmune is harnessing its ‘Immunology First’ approach to create first-in-category cancer medicines which aim to transform the lives of patients by delivering superior, long-term outcomes compared to current anti-cancer therapies. The EvolveImmune team has established a first-in-class and highly differentiated tumor-targeted T cell costimulation platform designed to re-invigorate adaptive immune responses in solid tumors. In addition, building upon research that originated from the Sidi Chen Laboratory at Yale University, EvolveImmune is leveraging a novel in vivo CRISPR-based target discovery platform to develop a broad portfolio of first-in-class therapeutics for unmet needs in oncology and immune diseases. The EvolveImmune team has 16,000+ square feet of custom-built lab and office space in Branford, CT to support biological development and clinical translational of programs advancing to the clinic.
For more information about EvolveImmune Therapeutics, please visit https://evolveimmune.com/.
The Role:
The company is seeking an entrepreneurial immunology-focused leader as Director of Immunobiology to lead the development and implementation of functional in vitro human assay systems, to drive successful candidate selection for first-in-class portfolio projects. A strong emphasis on tumor killing, cytokine production and T cell exhaustion assays as well as on multiparameter flow cytometry is expected. The successful candidate will also lead CRISPR-Cas9 screening in primary human cells and the validation of targets with the highest potential to sustain effector T cell responses. Close interactions with a team of scientists to guide the design and execution of these studies is expected. The candidate will also interface closely with the antibody discovery and protein engineering teams to drive lead optimization efforts. Collaboration with our network of academic partners is a key aspect of this role, including managing selected external research partnerships. Strong verbal and written communication skills, with evidence of a track record of scientific and project achievements in biopharma, are required.
We are looking for a candidate who enjoys working in a team and can leverage the growth opportunities that a matrixed environment provides. This is an exceptional opportunity for someone who is excited about drug discovery and is driven to translate these discoveries to novel therapeutics.
Major Responsibilities:
- Working closely with our protein design and engineering colleagues, establish functional ex vivo and in vivo studies to evaluate protein therapeutics and establish a data-driven decision for drug lead and candidate selection.
- Working closely with our in vivo pharmacology team design studies to evaluate drug candidate in vivo characteristics such as drug distribution properties, pharmacokinetic profile, early safety readouts, and disease state modifications in murine and humanized cancer models.
- Oversee immune co-culture assays including mixed lymphocyte reaction, T cell-tumor cell cytotoxicity assays and other phenotypic assessments of genetically modified immune cells to identify phenotypes associated with a knockout or genetic modification of a gene of interest.
- Lead immune cell target assessment and prioritization efforts based on CRISPR-Cas9 screen readouts by designing studies to evaluate target-focused gene editing in immune cells and biologics working closely with protein engineering colleagues.
- Contribute to the development of technologies for in vivo CRISPR-Cas9 screens by assisting in the design reagents and establishment of humanized tumor models.
- Ensure that biology team members keep detailed records of experiments in electronic notebooks, analyze data and prepare and deliver presentations to research team members and members of our executive leadership team.
Qualifications and Experience:
- PhD in Immunology or related field with postdoctoral experience and 7+ years of industry experience and experience in the development of immunotherapies or cell therapies.
- Extensive experience in cellular immunology in a translational biology setting, including experience immunotherapy or cell therapy target discovery and technical experience in assaying immune cell ex vivo and in vivo.
- Experience in the design and execution of CRISPR-Cas9 genetic screens in primary immune cells.
- Technical expertise to assist team members performing multi-color flow cytometry and Fluorescence Assisted Cell Sorting (FACS)
- Proven ability to manage drug discovery and development teams as demonstrated by a strong publication, patent and/or drug development record.
EvolveImmune will provide a competitive compensation package based on the level of the experience of the candidate.
EvolveImmune Therapeutics, Inc. is an equal opportunity employer.
Principals only.
Qualified applicants should apply using this link.
Who We Are
EvolveImmune Therapeutics is a next-generation immunotherapy platform company based in the Yale/New Haven biotechnology ecosystem with laboratories in Branford and Farmington, CT. EvolveImmune is harnessing its ‘Immunology First’ approach to create first-in-category cancer medicines which aim to transform the lives of patients by delivering superior, long-term outcomes compared to current anti-cancer therapies. The EvolveImmune team has established a first-in-class and highly differentiated tumor-targeted T cell costimulation platform designed to re-invigorate adaptive immune responses in solid tumors. In addition, building upon research that originated from the Sidi Chen Laboratory at Yale University, EvolveImmune is leveraging a novel in vivo CRISPR-based target discovery platform to develop a broad portfolio of first-in-class therapeutics for unmet needs in oncology and immune diseases.
The Role
We are seeking a Senior Scientist to join Protein Biotherapeutic group and contribute to a team effort to develop next-generation immunotherapies for effective cancer treatment. The core focus of this group is to use a multi-disciplinary approach to identify and validate tumor intrinsic, tumor micro-environment or immune cell targets tractable to therapeutic targeting, discover antibodies that selectively bind to these targets and use these antibodies to develop novel immunotherapeutic platforms that engage immune cells for efficient antitumor response.
A qualified candidate is a highly motivated and creative individual with substantial experience in protein biochemistry, protein/antibody expression and purification from mammalian cells using state of the art chromatography systems. A successful candidate will be responsible for protein and vector engineering, extensive molecular biology, tissue culture and cell biology work including, protein expression/purification, biophysical characterization, HT cloning, PCR/qPCR, cell line engineering and stable cell line generation. The candidate will also work closely with other members of the Biotherapeutic and Biology team members and contribute to protein/antibody expression and purification, biophysical characterizations, and target validation.
The successful candidate will collaborate with the Immune Discovery team for functional evaluation of the therapeutics leads using human PBMC or enriched human immune cell co-cultures assays to evaluate tumor-immune cell engagement, cytokine release profiles and immune phenotype assessment.
The successful candidate will be a clear communicator as well as effective collaborator, will demonstrate professional verbal and written communication, be capable of presenting scientific results to multidisciplinary teams and will contribute to writing scientific publications.
The colleague will interact with contract research organization (CROs) representatives, technician scientists in industry and academic centers and organizational leaders to contribute to highly integrative drug discovery and development effort.
We are looking for candidates who enjoy working in a team and can leverage the growth opportunities that a matrixed environment provides. This is an exceptional opportunity for someone who is excited about drug discovery and development and is driven to translate our discoveries into novel therapeutics.
Responsibilities
- Protein/antibody expression and purification from mammalian cells using affinity chromatography and size exclusion/IEX chromatography.
- Protein/antibody and bispecific antibody engineering, and expression vector engineering (transient and stable expression).
- Support biophysical characterization of proteins and antibodies using state of the art technologies for binding kinetics (SPR/BLI) and for biophysical properties ( DSC, CE, ELISA and other advanced molecular biology techniques).
- Tissue culture, cell line engineering, and stable cell line generation.
- Work in a team effort to establish biophysical and cell-based assays for antibody prioritization toward lead selection.
- Support target validation efforts by high throughput variable heavy and variable light chain antibody sequence cloning and reformatting, protein design and engineering.
- Collaborate and develop close scientific partnership with other functional areas across different teams.
- Help build a culture that embraces scientific excellence and continuous learning to increase our team’s ability to deliver novel drug development opportunities through rapid incorporation of emerging biotechniques on the leading-edge of oncology drug discovery.
- This role is a full time, in-person position in EvolveImmune’s laboratories in Branford CT.
Qualifications
Basic Qualifications
- PhD in Molecular Biology/Biochemistry/Cancer Biology or related discipline with at least 1-3 years industry experience; or MS in Molecular Biology/Cancer Biology/Biochemistry or related discipline with 3-5 years of industry experience.
- Ability to learn new techniques quickly and follow established protocols with precision.
- Perform tasks independently and able to interpret and communicate results.
- Excellent communication and presentation skills.
- Strong interpersonal skills and ability to work in team-based environment
Preferred Qualifications
- Strong hands-on experience in antibody expression/purification using affinity chromatography, SEC/IEX/HIC (AKTA FPLC Avant/Pure).
- Strong hands-on experience in Protein/antibody/bispecific antibody engineering and vector engineering.
- Proficient in biophysical characterization of protein/antibody using state of the art technologies including SPR (Biacore), BLI (Octet), DSC, aSEC/HIC/IEX (Agilent HPLC systems), LabChip (cGE), SDS-PAGE gel, ELISA.
- Proficiency in advanced molecular cloning techniques (infusion cloning/Gateway cloning), tissue culture techniques, cell line engineering, and stable cell line generation.
- Experience in protein display technologies such as phage display and/or yeast display, along with hands-on experience in library creation is a plus.
- In depth knowledge in immunology, immunooncology and immune cell biology is a plus
Physical/Mental Requirements
- Ability to perform complex and automated sequence and assay data analysis
- Must be able to wear personal protective equipment and adhere to biological safety consideration of the laboratory environment as defined by laboratory manager or group Directors.
- Must be able to handle mouse derived and human cell lines, and tissues.
- There will be less than 5% travel.
Other
EvolveImmune Therapeutics requires all employees to be fully vaccinated against COVID-19.
EvolveImmune Therapeutics is an equal opportunity employer.
Principals only.
Qualified applicants should apply using this link.
About Our Locations
It is a short drive to local amenities on the Connecticut shoreline, as well as to New Haven and Yale University. EvolveImmune has additional laboratories in Farmington, Connecticut as part of the UCONN Technology Incubator Program.
In 2020, EvolveImmune opened a new, start-of-the art laboratory and office facility in Branford, Connecticut.
